MedPage Today -- Medical device company NeoVista, Inc., recently announced one-year results from its MERITAGE study in patients with wet age-related macular degeneration, a leading cause of vision loss in older Americans. Researchers found that a single treatment with the California-based company’s EpiRetinal Brachytherapy device stabilized visual acuity in 79 percent of patients, while nearly half of patients experienced improved visual acuity. The results were presented on October 15th at the American Academy of Ophthalmology meeting.